Amgen, Inc. (NASDAQ:AMGN)

CAPS Rating: 4 out of 5

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

Recs

2
Player Avatar Jorgedig (< 20) Submitted: 12/1/2007 12:25:41 PM : Underperform Start Price: $50.93 AMGN Score: -95.02

I sold my Amgen just before the new, strict Medicare guidelines came through on the use of Aranesp to treat chemotherapy-induced anemia.

I work in a cancer clinic, and we are very concerned that many of our patients are denied this important drug until their hematocrits are spriralling down towards critically low. Medicare cites potential risks, but we know it's all about $$.

I like Amgen though, and would like to revise this pick once they overcome the layoffs and if they can recoup the lost profits from the Medicare reimbursement fiasco.

Member Avatar phyrne (37.63) Submitted: 4/16/2010 9:02:33 AM
Recs: 0

and now in 2010 what are you views?thankyou!

Featured Broker Partners


Advertisement